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The neurosensory retina is a complex ecosystem
composed of precisely layered and diverse neurons,
multiple vascular plexuses, and glial cells. It is
here that visual signals from the environment
are processed and conducted through the optic
nerve to the visual cortex to create the vivid images that humans see. The relationship of the
neurosensory retina to the brain is fascinating
because it is the only extension of the central
nervous system that can be easily visualized and
is readily accessible to interventional therapies.
Photoreceptors are specialized neurons in the
retina that sense photons of light and initiate
their transduction into electrical signals. Diseases
that affect the function and survival of photoreceptors can lead to blindness. These include
inherited retinal degenerations, acquired retinopathies such as retinal detachments, and diseases of
aging such as age-related macular degeneration.1
The past decade in vision science has been
productive: many novel approaches have been
developed to prevent vision loss in diverse diseases. Conventional approaches use pharmacotherapy to improve photoreceptor function and
vision. Recent efforts have focused on gene
therapy for conditions in which mutations within
photoreceptors or retinal pigment epithelial (RPE)
cells affect photoreceptor function and survival.
These efforts culminated in the regulatory approval of a new intraocular gene therapy for biallelic RPE65-associated gene mutations in retinal
dystrophies.2 A limitation of these approaches is
that they must be implemented relatively early in
the course of the disease, before substantial
photoreceptor damage occurs. The transplantation of embryonic stem cell–derived or induced
pluripotent stem cell–derived RPE cells is being
examined in early-stage clinical trials involving
humans. In addition, the transplantation of photoreceptors or their precursors is in preclinical
development.3 Another innovative strategy has
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been to bypass photoreceptors and initiate visual
transduction by means of optogenetics (a technique that uses genetic engineering to express
light-sensitive ion channels in neurons) or by
means of implantable electronic devices that circumvent photoreceptors. These strategies have
tremendous potential given the regulatory approval of an intraocular, implantable device for
patients with severe vision loss.4
In an intriguing study conducted by Mahato
et al.,5 the investigators pharmacologically reprogrammed fibroblasts into rod photoreceptorlike cells that they call chemically induced photoreceptor-like cells (CIPCs). Using small molecules,
they found that fibroblasts from mice and humans can be reprogrammed into CIPCs. Reprogrammed CIPCs express photoreceptor markers
such as rhodopsin and CRX (a transcription factor
that is critical to the development of photoreceptor cells). Moreover, their transcriptomic profiles
are enriched in rod-specific genes.
Mahato et al. transplanted CIPCs into the
eyes of mice with severe retinal degeneration and
found synaptic connections between and activation by these cells of the inner retinal circuitry.
Although they observed variability in the number of CIPCs that survived after transplantation,
as well as variability in the results of functional
tests such as pupillary response, light aversion,
modified optokinetic testing, and electroretinography, they also observed generally improved retinal responses after the transplantation of CIPCs.
Molecular mechanisms that have been proposed for the transdifferentiation of fibroblasts
into CIPCs involve mitochondrial translocation
of AXIN2, which activates mitochondrial reactive oxygen species (ROS). The mitochondrial
ROS in turn activate NF-κB (nuclear factor kappalight-chain enhancer of activated B cells), which
up-regulates the neural transcription factor Ascl1
(Fig. 1). Further research is needed to determine
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Figure 1. Restoring Retinal Function with Chemically Induced Cells.
In the healthy neurosensory retina, visual transduction begins when light photons reach rod and cone photoreceptors. The information
is processed through the layered neuroglial network and conveyed by ganglion-cell axons through the optic nerve to the brain. Vision
loss occurs in diseases in which photoreceptors become dysfunctional or die. The transplantation of cells such as chemically induced
photoreceptor-like cells into the subretinal space in murine models opens a new avenue for future research to examine the role of cell
transplantation in patients with blinding retinal diseases.

the efficiency of reprogramming, the effective- donor and host cells that may account for some
ness and magnitude of synaptic reconnectivity, of the functional effects. Nonetheless, these preand the possibility of material transfer between liminary findings support a new, albeit tentative,
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strategy for the treatment of diverse retinal diseases in which photoreceptor death has caused
vision loss and in which pharmacologic and genetherapy approaches, which require live photoreceptors, would not be appropriate. CIPCs deserve
careful examination in additional preclinical
studies before clinical development strategies
are considered. Additional variables for further
evaluation include assessments of long-term survival of CIPCs within the retina, measurements
of visual function that are clinically meaningful,
and the immunogenicity of transplanted cells.
The new and emerging strategies for the rescue,
regeneration, and replacement of photoreceptors
suggest a bright future in the fight to preserve
and restore vision in blinding eye diseases.
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